Citigroup Initiates Coverage On Cogent Biosciences with Buy Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebowitz initiates coverage on Cogent Biosciences with a Buy rating and sets a price target of $11.

February 08, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has initiated coverage on Cogent Biosciences with a Buy rating and a price target of $11.
Analyst ratings, especially from a major financial institution like Citigroup, can significantly influence investor perception and stock price. A Buy rating combined with a specific price target provides a positive outlook for the stock, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100